OUP and Sofinnova Partners invested in 28-7 Therapeutics to take its series A round to $82.8m, enabling the Harvard spinout to pursue accelerated development of its cancer drug pipeline.

Twentyeight-Seven (28-7) Therapeutics, a US-based cancer drug development spinout of Harvard University, has extended its series A round to $82.8m with a $15m second tranche backed by spinout-focused investment firm Osage University Partners. The extension was led by venture capital firm Sofinnova Partners and followed an initial $65m series A close in September 2018 co-led by…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.